Trials / Completed
CompletedNCT04880616
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects With Essential Tremor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the efficacy, safety, and tolerability of NBI-827104 in adults with essential tremor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBI-827104 | Capsules for oral administration |
| DRUG | Placebo | Capsules matching NBI-827104 for oral administration |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2022-05-25
- Completion
- 2022-06-08
- First posted
- 2021-05-11
- Last updated
- 2022-07-12
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04880616. Inclusion in this directory is not an endorsement.